Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Potential Non-Invasive Alternatives to Self-Monitoring Devices
Home Care Management of Diabetes
Overcoming the Challenges of Diabetes: Talking With an 'Amazing Race' Winner
Hypoglycemia on a Clinically Relevant Level
Practice vs. Accountability in Diabetes Care
Shaping Diabetes Management With Digital Technology and Genomics
New Experimental Treatments for Diabetic Wounds
Catering Drug Therapies To Specific Subsets of Patients with Type 2 Diabetes
Optimizing Athletic Performance in Type 1 Diabetes
Structured Self-Monitoring of Blood Glucose
The Key to Successful Adherence to Diabetes Drug Regimens
The Potential of Statins to Prevent Diabetic-Related Blindness
The Impact of Race and Ethnicity on Insulin Regimens
Using Video Games to Improve Children’s Diets
The Treatment of Transplant Patients With Diabetes
Meal Time Interventions for Patients with Type 2 Diabetes
The Value of Behavior Change in Diabetes, for Patients and Professionals
New Guidelines for Exercise and Type 2 Diabetes
Use of Glucagon and Insulin in a Closed-Loop System
Changes in Diabetes Care
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video